demonstrated the presence of bone-associated proteins, such as osteopontin, osteocalcin, bone morphogenic protein (BMP)-2, osteonectin, and matrix Gla protein (MGP) in human calcified, atherosclerotic plaques. [5] [6] [7] [8] [9] In this study, we aimed to evaluate whether serum levels of BMP-4 and MGP differed in patients who were found to have normal epicardial coronary arteries or a culprit lesion in the coronary angiography leading to acute coronary syndrome (ACS).
| MATERIALS AND METHODS

| Study population
Patients admitted to emergency department with the diagnosis of 
| Measurement of BMP-4 and MGP levels
Ten milliliters of peripheral venous blood samples were obtained from patients prior to coronary angiography and immediately centrifuged.
Serum samples were immediately centrifuged and stored at −80°C until assayed. Prior to analysis, the frozen serum samples were rapidly thawed and brought to room temperature and assayed for BMP-4 and MGP Table 1 . Among baseline characteristics, co-morbidities or medications did not significantly differ between the age and gendermatched study (n=45) and control groups (n=45). Fasting blood glucose (P=.026) and CRP (P<.001) levels were significantly higher; HDLcholesterol levels were significantly lower (P<.001) in the study group when compared to the controls. In the study group, MGP (<0.001) and BMP-4 (<0.001) levels were also significantly elevated when compared to subjects with normal coronary arteries. Comparison of serum MGP and BMP-4 levels regarding the presence of conventional cardiovascular risk factors and medications is given in Table 2 . Serum MGP and BMP-4 levels did not significantly differ between patient groups when history of hypertension, diabetes mellitus, smoking, family history of coronary artery disease (CAD), or medication use (beta-blockers, statins, ACEi/ARBs) were taken into account (P>.05).
| Statistical analysis
| RESULTS
Correlation between baseline characteristics and serum MGP and BMP-4 levels are shown in 
| DISCUSSION
This is the first study in the literature evaluating serum BMP-4 and MGP levels in patients with ACS compared to patients with normal epicardial coronary arteries. Our study has demonstrated that levels of both BMP-4 and MGP were independently associated with ACS diagnosis and they were significantly correlated with several conventional CV risk factors.
The role of BMPs in vascular calcification and atherosclerosis has been investigated in previous studies. BMP-2 has been demonstrated to mediate human coronary artery smooth muscle cell (CASMC) calcification in a dose-dependent way, due to an increase in intracellular Ca 2+ deposition. 10 Oscillatory shear stress, that occurs particularly in branching vessels, has been reported to induce BMP-4, which results in endothelial dysfunction and inflammation via nuclear factor-kB, nicotinamide adenine dinucleotide phosphate oxidase, and cyclooxygenase-2 upregulation, [11] [12] [13] which is shown to be restored by inhibition of BMP-4 in diabetic mice models.
14 Both BMP-2 and BMP-4 expression have been shown to be increased in human atherosclerotic plaques and the overlying endothelium of early atherosclerotic lesions within the coronary artery.
12,15
Similarly, our study has demonstrated that serum BMP-4 levels were significantly elevated in patients with ACS and an independent association persisted when other CV risk factors were taken into account.
BMP-4 levels also significantly correlated with another inflammatory marker, CRP.
However, controversial findings do also exist. For instance, in patients with type 2 diabetes, serum BMP-4 levels were found to be inversely correlated with intima-media thickness and cardio-ankle vascular index, which are markers of subclinical atherosclerosis.
16
In a small study, 17 serum BMP-4 levels were increased in subjects with chronic kidney disease and CAD compared with those without CAD, but there was no difference among patients without chronic kidney disease. In a recent study, after adjustment for other CV risk factors, a high serum BMP-4 level was an independent predictor for a decreased risk of multivessel disease (P=.01) in 1.044 consecutive patients who underwent elective coronary angiography and PCI. 18 The available literature suggests that this condition may be attributed to BMP-4 deposition into the atherosclerotic vascular tissue.
12,15
The matrix Gla protein, an inhibitor of vessel and cartilage calcification, 19, 20 has also been shown to be strongly expressed in human calcified atherosclerotic plaques in previous studies. Due to its plaque calcification-modulating properties, 21 MGP gene expression has been suggested to be induced in response to atherosclerosis.
22
A strong positive correlation between serum MGP concentrations and artery calcification has been reported in the rat, with threefold elevation in serum MGP in those with the greatest artery calcification, 23 and authors have suggested that this may be secondary to increased local synthesis of MGP for the purpose of slowing the progression of arterial calcification. Nevertheless, it has been observed that an increase in only serum levels of MGP, without a concomitant increase in its gene expression in the arterial walls, does not inhibit the ectopic mineralization observed in mice lacking MGP. 24 In accordance with some previous studies that showed elevated serum MGP levels in patients with severe atherosclerosis, 25, 26 our study has demonstrated that serum MGP levels were significantly higher in patients with ACS.
This may be due to the fact that plaque rupture and thrombosis are determined by the balance between plaque structural stress (PSS) and material strength, and degree of calcification of a plaque has a profound effect on PSS. 27 In addition, our study has shown that serum MGP levels were significantly correlated with several CV risk factors and were independently associated with ACS occurrence. This is similar to another study showing the association between MGP and individual CHD risk factors and the Framingham CHD risk score in men and women free of clinically apparent CHD. 28 On the other hand, the available data from other studies in humans are conflicting. Decreased serum MGP levels have been found to be 
| Study limitations
There are some limitations of this study. First, the lack of follow-up in the study population limits the complete assessment of the role of these biomarkers in the ACS process. Second, a larger study population would have increased the power of the study. Third, this study only reveals an association, not a causal relationship. Further prospective studies with larger population are necessary.
| CONCLUSION
This study shows that serum BMP-4 and MGP are independently associated with ACS occurrence when adjusted for other CV risk factors.
These biomarkers may have a diagnostic potential in ACS patients.
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